|
1
|
Gridelli C, Rossi A, Carbone DP, Guarize
J, Karachaliou N, Mok T, Petrella F, Spaggiari L and Rosell R:
Non-small-cell lung cancer. Nat Rev Dis Primers. 1:150092015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rosell R, Bivona TG and Karachaliou N:
Genetics and biomarkers in personalisation of lung cancer
treatment. Lancet. 382:720–731. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Skjefstad K, Johannessen C, Grindstad T,
Kilvaer T, Paulsen EE, Pedersen M, Donnem T, Andersen S, Bremnes R,
Richardsen E, et al: A gender specific improved survival related to
stromal miR-143 and miR-145 expression in non-small cell lung
cancer. Sci Rep. 8:85492018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Custodio A, Méndez M and Provencio M:
Targeted therapies for advanced non-small-cell lung cancer: Current
status and future implications. Cancer Treat Rev. 38:36–53. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Selbach M, Schwanhäusser B, Thierfelder N,
Fang Z, Khanin R and Rajewsky N: Widespread changes in protein
synthesis induced by microRNAs. Nature. 455:58–63. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Doench JG and Sharp PA: Specificity of
microRNA target selection in translational repression. Genes Dev.
18:504–511. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lv L and Wang X: MicroRNA-296 targets
specificity protein 1 to suppress cell proliferation and invasion
in cervical cancer. Oncol Res. 26:775–783. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li H, Li J, Shi B and Chen F: MicroRNA-296
targets AKT2 in pancreatic cancer and functions as a potential
tumor suppressor. Mol Med Rep. 16:466–472. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He Z, Yu L, Luo S, Li M, Li J, Li Q, Sun Y
and Wang C: miR-296 inhibits the metastasis and
epithelial-mesenchymal transition of colorectal cancer by targeting
S100A4. BMC Cancer. 17:1402017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li H, Ouyang XP, Jiang T, Zheng XL, He PP
and Zhao GJ: MicroRNA-296: A promising target in the pathogenesis
of atherosclerosis? Mol Med. 24:122018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu C, Li S, Chen T, Hu H, Ding C, Xu Z,
Chen J, Liu Z, Lei Z, Zhang HT, et al: MiR-296-5p suppresses cell
viability by directly targeting PLK1 in non-small cell lung cancer.
Oncol Rep. 35:497–503. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo W, Lin Y, Meng S, Guo Y, Zhang J and
Zhang W: miRNA-296-3p modulates chemosensitivity of lung cancer
cells by targeting CX3CR1. Am J Transl Res. 8:1848–1856.
2016.PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu X, Chen Q, Yan J, Wang Y, Zhu C, Chen
C, Zhao X, Xu M, Sun Q, Deng R, et al: MiRNA-296-3p-ICAM-1 axis
promotes metastasis of prostate cancer by possible enhancing
survival of natural killer cell-resistant circulating tumour cells.
Cell Death Dis. 4:e9282013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang X, Hu Y, Cui J, Zhou Y and Chen L:
Coordinated targeting of MMP-2/MMP-9 by miR-296-3p/FOXCUT exerts
tumor-suppressing effects in choroidal malignant melanoma. Mol Cell
Biochem. 445:25–33. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ba Y, Liao H, Liu T, Zeng X, Xiao F, Luo
L, Guo H and Guo L: MiR-296-3p regulates cell growth and multi-drug
resistance of human glioblastoma by targeting ether-à-go-go (EAG1).
Eur J Cancer. 49:710–724. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li H, Liu G, Xia L, Zhou Q, Xiong J, Xian
J, Du M, Zhang L, Liao L, Su X, et al: A polymorphism in the DNA
repair domain of APEX1 is associated with the radiation-induced
pneumonitis risk among lung cancer patients after radiotherapy. Br
J Radiol. 87:201400932014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kelley MR, Cheng L, Foster R, Tritt R,
Jiang J, Broshears J and Koch M: Elevated and altered expression of
the multifunctional DNA base excision repair and redox enzyme
Ape1/ref-1 in prostate cancer. Clin Cancer Res. 7:824–830.
2001.PubMed/NCBI
|
|
20
|
Wang D, Luo M and Kelley MR: Human
apurinic endonuclease 1 (APE1) expression and prognostic
significance in osteosarcoma: Enhanced sensitivity of osteosarcoma
to DNA damaging agents using silencing RNA APE1 expression
inhibition. Mol Cancer Ther. 3:679–686. 2004.PubMed/NCBI
|
|
21
|
Yang S, Irani K, Heffron SE, Jurnak F and
Meyskens FL Jr: Alterations in the expression of the
apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in
human melanoma and identification of the therapeutic potential of
resveratrol as an APE/Ref-1 inhibitor. Mol Cancer Ther.
4:1923–1935. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Woo J, Park H, Sung SH, Moon BI, Suh H and
Lim W: Prognostic value of human apurinic/apyrimidinic endonuclease
1 (APE1) expression in breast cancer. PLoS One. 9:e995282014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim MH, Kim HB, Yoon SP, Lim SC, Cha MJ,
Jeon YJ, Park SG, Chang IY and You HJ: Colon cancer progression is
driven by APEX1-mediated upregulation of Jagged. J Clin Invest:.
(pii): 655212013.PubMed/NCBI
|
|
24
|
Yang J, Yang D, Cogdell D, Du X, Li H,
Pang Y, Sun Y, Hu L, Sun B, Trent J, et al: APEX1 gene
amplification and its protein overexpression in osteosarcoma:
Correlation with recurrence, metastasis, and survival. Technol
Cancer Res Treat. 9:161–169. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Puglisi F, Aprile G, Minisini AM, Barbone
F, Cataldi P, Tell G, Kelley MR, Damante G, Beltrami CA and Di
Loreto C: Prognostic significance of Ape1/ref-1 subcellular
localization in non-small cell lung carcinomas. Anticancer Res.
21:4041–4049. 2001.PubMed/NCBI
|
|
26
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: Its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lv X, Li CY, Han P and Xu XY:
MicroRNA-520a-3p inhibits cell growth and metastasis of non-small
cell lung cancer through PI3K/AKT/mTOR signaling pathway. Eur Rev
Med Pharmacol Sci. 22:2321–2327. 2018.PubMed/NCBI
|
|
29
|
Tsurutani J, Fukuoka J, Tsurutani H, Shih
JH, Hewitt SM, Travis WD, Jen J and Dennis PA: Evaluation of two
phosphorylation sites improves the prognostic significance of Akt
activation in non-small-cell lung cancer tumors. J Clin Oncol.
24:306–314. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Testa JR and Bellacosa A: AKT plays a
central role in tumorigenesis. Proc Natl Acad Sci USA.
98:10983–10985. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bruhn MA, Pearson RB, Hannan RD and
Sheppard KE: AKT-independent PI3-K signaling in cancer-emerging
role for SGK3. Cancer Manag Res. 5:281–292. 2013.PubMed/NCBI
|
|
32
|
Wang XX, Cheng Q, Zhang SN, Qian HY, Wu
JX, Tian H, Pei DS and Zheng JN: PAK5-Egr1-MMP2 signaling controls
the migration and invasion in breast cancer cell. Tumour Biol.
34:2721–2729. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Du Q, Liu J, Zhang X, Zhang X, Zhu H, Wei
M and Wang S: Propofol inhibits proliferation, migration, and
invasion but promotes apoptosis by regulation of Sox4 in
endometrial cancer cells. Braz J Med Bio Res. 51:e68032018.
|
